[1]
|
Mach, F., Baigent, C., Catapano, A.L., et al. (2020) 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. European Heart Journal, 41, 111-188. https://doi.org/10.1093/eurheartj/ehz455
|
[2]
|
Diffenderfer, M.R. and Schaefer, E.J. (2014) The Composition and Metabolism of Large and Small LDL. Current Opinion in Lipidology, 25, 221-226. https://doi.org/10.1097/MOL.0000000000000067
|
[3]
|
Rizzo, M. and Berneis, K. (2007) Who Needs to Care about Small, Dense Low-Density Lipoproteins? International Journal of Clinical Practice, 61, 1949-1956. https://doi.org/10.1111/j.1742-1241.2007.01596.x
|
[4]
|
Ivanova, E.A., Myasoedova, V.A., Melnichenko, A.A., et al. (2017) Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxidative Medicine and Cellular Longevity, 2017, Article ID: 1273042. https://doi.org/10.1155/2017/1273042
|
[5]
|
Masuda, D., Miyata, Y., Matsui, S., et al. (2020) Omega-3 Fatty Acid Ethyl Esters Improve Low-Density Lipoprotein Subclasses without Increasing Low-Density Lipoprotein-Cholesterol Levels: A Phase 4, Randomized Study. Atherosclerosis, 292, 163-170. https://doi.org/10.1016/j.atherosclerosis.2019.11.014
|
[6]
|
Berneis, K.K. and Krauss, R.M. (2002) Metabolic Origins and Clinical Significance of LDL Heterogeneity. Journal of Lipid Research, 43, 1363-1379. https://doi.org/10.1194/jlr.R200004-JLR200
|
[7]
|
Jin, X., Yang, S., Lu, J., et al. (2022) Small, Dense Low-Density Lipoprotein-Cholesterol and Atherosclerosis: Relationship and Therapeutic Strategies. Frontiers in Cardiovascular Medicine, 8, Article ID: 804214. https://doi.org/10.3389/fcvm.2021.804214
|
[8]
|
Moore, K.J., Sheedy, F.J. and Fisher, E.A. (2013) Macrophages in Atherosclerosis: A Dynamic Balance. Nature Reviews Immunology, 13, 709-721. https://doi.org/10.1038/nri3520
|
[9]
|
Steinberg, D., Parthasarathy, S., Carew, T.E., et al. (1989) Beyond Cholesterol. The New England Journal of Medicine, 320, 915-924. https://doi.org/10.1056/NEJM198904063201407
|
[10]
|
Ikezaki, H., Furusyo, N., Yokota, Y., et al. (2020) Small Dense Low-Density Lipoprotein Cholesterol and Carotid Intimal Medial Thickness Progression. Journal of Atherosclerosis and Thrombosis, 27, 1108-1122. https://doi.org/10.5551/jat.54130
|
[11]
|
Qiao, Y.N., Zou, Y.L. and Guo, S.D. (2022) Low-Density Lipoprotein Particles in Atherosclerosis. Frontiers in Physiology, 13, Article ID: 931931. https://doi.org/10.3389/fphys.2022.931931
|
[12]
|
Sakai, K., Koba, S., Nakamura, Y., et al. (2018) Small Dense Low-Density Lipoprotein Cholesterol Is a Promising Biomarker for Secondary Prevention in Older Men with Stable Coronary Artery Disease. Geriatrics & Gerontology International, 18, 965-972. https://doi.org/10.1111/ggi.13287
|
[13]
|
Tribble, D.L., Rizzo, M., Chait, A., et al. (2001) Enhanced Oxidative Susceptibility and Reduced Antioxidant Content of Metabolic Precursors of Small, Dense Low-Density Lipoproteins. The American Journal of Medicine, 110, 103-110. https://doi.org/10.1016/S0002-9343(00)00700-2
|
[14]
|
Li, G., Wu, H.-K., Wu, X.-W., et al. (2018) Small Dense Low Density Lipoprotein-Cholesterol and Cholesterol Ratios to Predict Arterial Stiffness Progression in Normotensive Subjects over a 5-Year Period. Lipids in Health and Disease, 17, Article No. 27. https://doi.org/10.1186/s12944-018-0671-2
|
[15]
|
Saleem, I., Aamir, M., Haroon, Z.H., et al. (2022) Small Dense Low-Density Lipoprotein Cholesterol as a Novel Biomarker of Coronary Heart Disease. Pakistan Armed Forces Medical Journal, 72, 1343-1346. https://doi.org/10.51253/pafmj.v72i4.8085
|
[16]
|
Balling, M., Nordestgaard, B.G., Varbo, A., et al. (2023) Small Dense Low-Density Lipoprotein Cholesterol and Ischemic Stroke. Annals of Neurology, 93, 952-964. https://doi.org/10.1002/ana.26598
|
[17]
|
Duran, E.K., Aday, A.W., Cook, N.R., et al. (2020) Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease. Journal of the American College of Cardiology, 75, 2122-2135. https://doi.org/10.1016/j.jacc.2020.02.059
|
[18]
|
Higashioka, M., Sakata, S., Honda, T., et al. (2020) Small Dense Low-Density Lipoprotein Cholesterol and the Risk of Coronary Heart Disease in a Japanese Community. Journal of Atherosclerosis and Thrombosis, 27, 669-682. https://doi.org/10.5551/jat.51961
|
[19]
|
Schaefer, E.J., Ikezaki, H., Diffenderfer, M.R., et al. (2023) Atherosclerotic Cardiovascular Disease Risk and Small Dense Low-Density Lipoprotein Cholesterol in Men, Women, African Americans and Non-African Americans: The Pooling Project. Atherosclerosis, 367, 15-23. https://doi.org/10.1016/j.atherosclerosis.2023.01.015
|
[20]
|
Tsai, M.Y., Steffen, B.T., Guan, W., et al. (2014) New Automated Assay of Small Dense Low-Density Lipoprotein Cholesterol Identifies Risk of Coronary Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 34, 196-201. https://doi.org/10.1161/ATVBAHA.113.302401
|
[21]
|
Zhang, J. and He, L. (2021) Relationship between Small Dense Low Density Lipoprotein and Cardiovascular Events in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. BMC Cardiovascular Disorders, 21, Article No. 169. https://doi.org/10.1186/s12872-021-01979-7
|
[22]
|
Ikezaki, H., Lim, E., Cupples, L.A., et al. (2021) Small Dense Low-Density Lipoprotein Cholesterol Is the Most Atherogenic Lipoprotein Parameter in the Prospective Framingham Offspring Study. Journal of the American Heart Association, 10, e019140. https://doi.org/10.1161/JAHA.120.019140
|
[23]
|
Kahn, R., Buse, J., Ferrannini, E., et al. (2005) The Metabolic Syndrome: Time for a Critical Appraisal: Joint Statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 28, 2289-2304. https://doi.org/10.2337/diacare.28.9.2289
|
[24]
|
Hoogeveen, R.C., Gaubatz, J.W., Sun, W., et al. (2014) Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 34, 1069-1077. https://doi.org/10.1161/ATVBAHA.114.303284
|
[25]
|
Berneis, K., Jeanneret, C., Muser, J., et al. (2005) Low-Density Lipoprotein Size and Subclasses Are Markers of Clinically Apparent and Non-Apparent Atherosclerosis in Type 2 Diabetes. Metabolism, 54, 227-234. https://doi.org/10.1016/j.metabol.2004.08.017
|
[26]
|
Hirano, T., Kodera, R., Hirashima, T., et al. (2022) Metabolic Properties of Lowdensity Lipoprotein (LDL) Triglycerides in Patients with Type 2 Diabetes, Comparison with Small Dense LDL-Cholesterol. Journal of Atherosclerosis and Thrombosis, 29, 762-774. https://doi.org/10.5551/jat.62789
|
[27]
|
Patti, A.M., Katsiki, N., Nikolic, D., et al. (2014) Nutraceuticals in Lipid-Lowering Treatment: A Narrative Review on the Role of Chitosan. Angiology, 66, 416-421. https://doi.org/10.1177/0003319714542999
|
[28]
|
Toth, P.P., Patti, A.M., Nikolic, D., et al. (2016) Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study. Frontiers in Pharmacology, 6, Article No. 299. https://doi.org/10.3389/fphar.2015.00299
|
[29]
|
Wang, L., Tao, L., Hao, L., et al. (2020) A Moderate-Fat Diet with One Avocado per Day Increases Plasma Antioxid Ants and Decreases the Oxidation of Small, Dense LDL in Adults with Overweight and Obesity: A Randomized Controlled Trial. The Journal of Nutrition, 150, 276-284. https://doi.org/10.1093/jn/nxz231
|
[30]
|
Medlow, P., McEneny, J., Murphy, M.H., et al. (2015) Lipoprotein Subfraction Oxidation in Acute Exercise and Ageing. Free Radical Research, 50, 345-353. https://doi.org/10.3109/10715762.2015.1109084
|
[31]
|
Kotani, K., et al. (2012) The Correlation between Small Dense LDL and Reactive Oxygen Metabolites in a Physical Activity Intervention in Hyperlipidemic Subjects. Journal of Clinical Medicine Research, 4, 161-166. https://doi.org/10.4021/jocmr870w
|
[32]
|
Dutheil, F., Walther, G., Chapier, R., et al. (2014) Atherogenic Subfractions of Lipoproteins in the Treatment of Metabolic Syndrome by Physical Activity and Diet—The RESOLVE Trial. Lipids in Health and Disease, 13, Article No. 112. https://doi.org/10.1186/1476-511X-13-112
|
[33]
|
Alizadeh-Fanalou, S., Nazarizadeh, A., Alian, F., et al. (2020) Small Dense Low-Density Lipoprotein-Lowering Agents. Biological Chemistry, 401, 1101-1121. https://doi.org/10.1515/hsz-2019-0426
|
[34]
|
马丽媛, 王增武, 樊静, 等. 《中国心血管健康与疾病报告2022》要点解读[J]. 中国全科医学, 2023, 26(32): 3975-3994.
|
[35]
|
Ray, K.K., Wright, R.S., Kallend, D., et al. (2020) Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. New England Journal of Medicine, 382, 1507-1519. https://doi.org/10.1056/NEJMoa1912387
|
[36]
|
Raal, F.J., Kallend, D., Ray, K.K., et al. (2020) Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. New England Journal of Medicine, 382, 1520-1530. https://doi.org/10.1056/NEJMoa1913805
|
[37]
|
Zhang, Y., Xu, R.X., Li, S., et al. (2015) Association of Plasma Small Dense LDL Cholesterol with PCSK9 Levels in Patients with Angiographically Proven Coronary Artery Disease. Nutrition, Metabolism and Cardiovascular Diseases, 25, 426-433. https://doi.org/10.1016/j.numecd.2015.01.006
|